Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
Add more filters










Publication year range
1.
Comp Biochem Physiol B Biochem Mol Biol ; 156(4): 237-43, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20363355

ABSTRACT

Supplies of marine fish oils are limited, and continued growth in aquaculture production dictates that lipid substitutes in fish diets must be used without compromising fish health and product quality. In this study, the total substitution of a fish meal and fish oil by a blend of vegetable meals (corn, soybean, wheat and lupin) and linseed oil in the diet of European sea bass (Dicentrachus labrax) was investigated. Two groups of European sea bass were fed with fish diet (FD) or vegetable diet (VD) for 9months. VD, totally deprived of eicosapentaenoate (EPA; 20:5n-3) and docosahexaenoate (DHA; 22:6n-3), revealed a nutritional deficiency and affected growth performance. Whilst VD induced a significant increase in fatty acid desaturase 2 (FADS2) and sterol binding regulatory element-binding protein 1 (SREBP-1) mRNA levels, the desaturation rate of [1-(14)C]18:3n-3 into [1-(14)C]18:4n-3, analysed in microsomal preparations using HPLC method, did not show an upregulation of FADS2 activities in liver and intestine of fish fed VD. Moreover Western-blot analysis did not revealed any significant difference of FADS2 protein amount between the two dietary groups. These data demonstrate that sea bass exhibits a desaturase (FADS2) activity whatever their diet, but a post-transcriptional regulation of fads2 RNA prevents an increase of enzyme in fish fed a HUFA-free diet. This led to a lower fish growth and poor muscle HUFA content.


Subject(s)
Bass/metabolism , Diet , Fatty Acid Desaturases/metabolism , Fish Proteins/metabolism , Animal Feed , Animals , Aquaculture , Bass/genetics , Bass/growth & development , Fatty Acid Desaturases/genetics , Fatty Acids/analysis , Fish Proteins/genetics , Gene Expression Regulation , Intestines/enzymology , Liver/enzymology , PPAR alpha/genetics , PPAR alpha/metabolism , Sterol Regulatory Element Binding Protein 1/genetics , Sterol Regulatory Element Binding Protein 1/metabolism , Vegetables
2.
Toxicol Lett ; 167(3): 221-30, 2006 Dec 15.
Article in English | MEDLINE | ID: mdl-17084997

ABSTRACT

The involvement of cytochromes P450 (CYPs) in the oxidation of ethanol into acetaldehyde was investigated by using 16 recombinant human CYP isoforms. Apparent K(m) and V(m) were determined for CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4 and CYP4A11. All of the tested CYPs, except CYP2A6 and CYP2C18, metabolized ethanol into significant amounts of acetaldehyde and displayed K(m) values around 10mM. The significant correlation found between ethanol oxidation and CYP2E1, CYP3A4 and CYP1A2 catalytic activities in a panel of human liver microsomes confirmed the strong implication of these CYPs in ethanol metabolism. The contribution of CYP2C isoforms which are the most abundant in the liver after CYP3A4, was studied using selective inhibitors either with recombinant CYP2C isoforms or in human liver microsomes. Tienilic acid (100 microM) and ticlopidine (20 microM), mechanism-based inhibitors of CYP2C9 and CYP2C19, respectively, decreased ethanol oxidation by 8+/-1.2% and 7.6+/-1.6% in human liver microsomal samples while selective inhibitors of CYP2E1 (DEDTC 100 microM), CYP3A4 (TAO 50 microM) and CYP1A2 (furafylline 25 microM) decreased it by 11.9+/-2.1%, 19.8+/-1.9% and 16.3+/-3.9%, respectively. As ethanol can be metabolized by most of CYPs, it helps to explain or predict alcohol-xenobiotics interactions which are of high importance in medical prescription.


Subject(s)
Acetaldehyde/metabolism , Aryl Hydrocarbon Hydroxylases/physiology , Ethanol/metabolism , Microsomes, Liver/metabolism , Mixed Function Oxygenases/physiology , Catalysis , Cytochrome P-450 CYP2C19 , Cytochrome P-450 CYP2C8 , Cytochrome P-450 CYP2C9 , Humans , Oxidation-Reduction , Recombinant Proteins/pharmacology
3.
Toxicol Lett ; 125(1-3): 83-91, 2001 Dec 15.
Article in English | MEDLINE | ID: mdl-11701226

ABSTRACT

Resveratrol (RESV), present at concentrations of about 10 microM in red wine, has been found to inhibit events associated with tumor initiation, promotion and progression. The mechanism involved could be the inhibition of activities catalyzed by cytochromes P450 (CYPs), which activate procarcinogens. This led us to investigate the inhibitory effect of RESV on CYP1A, CYP2E1 and CYP3A enzymatic activities and to compare it to that of non volatile compounds present in red wine. Red wine solids (RWS) were prepared by evaporating one volume of red wine to dryness followed by reconstitution with five volumes of buffer (20% natural strength). CYP activities were determined in microsomes from rat liver, human liver or cells containing cDNA-expressed CYPs. Testosterone, chlorzoxazone, and ethoxyresorufin were used as selective substrates for CYP3A, CYP2E1 and CYP1A1/1A2, respectively. RESV and RWS were found to be irreversible (probably mechanism-based) inhibitors for CYP3A4 and non competitive reversible inhibitors for CYP2E1. Their inhibitory potency was assessed using IC(50) values that were found within 4-150 microM for RESV and 0.3-9% natural strength for RWS. Non volatile compounds of other beverages such as white wine, grape juice or Xtra Old Cognac(R) displayed lower inhibitory effect on CYP activities than RWS. When considering the concentration of RESV in red wine (2 microM for 20% natural strength), it appears that RSW inhibitory effect was not only due to RESV, but also to other compounds whose identification would prove to be worthwhile because of their possible chemopreventive properties.


Subject(s)
Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 CYP1A1/antagonists & inhibitors , Cytochrome P-450 CYP1A2 Inhibitors , Cytochrome P-450 CYP2E1 Inhibitors , Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Oxidoreductases, N-Demethylating/antagonists & inhibitors , Stilbenes/pharmacology , Wine , Animals , Cytochrome P-450 CYP3A , Humans , Microsomes, Liver/enzymology , Rats , Rats, Wistar , Resveratrol
4.
Toxicol Lett ; 124(1-3): 47-58, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11684357

ABSTRACT

Methyl t-butyl ether (MTBE), ethyl t-butyl ether (ETBE), and t-amyl methyl ether (TAME) are three alkoxyethers added to gasoline to improve combustion and thereby to reduce the level of carbon monoxide and aromatic hydrocarbons in automobile exhaust. Oxidative demethylation of MTBE and TAME and deethylation of ETBE by CYP enzymes results in the formation of tertiary alcohols and aldehydes, both potentially toxic. The metabolism of these three alkoxyethers was studied in a panel of 12 human liver microsomes. The relatively low apparent Km(1) was 0.25+/-0.17 (mean+/-SD), 0.11+/-0.08 and 0.10+/-0.07 mM and the high apparent Km(2) was 2.9+/-1.8, 5.0+/-2.7 and 1.7+/-1.0 mM for MTBE, ETBE and TAME, respectively. Kinetic data, correlation studies, chemical inhibition and metabolism by heterologously expressed human CYPs support the assertion that the major enzyme involved in MTBE, ETBE and TAME metabolisms is CYP2A6, with a minor contribution of CYP3A4 at low substrate concentration.


Subject(s)
Air Pollutants/metabolism , Cytochrome P-450 Enzyme System/metabolism , Ethyl Ethers/metabolism , Methyl Ethers/metabolism , Air Pollutants/pharmacokinetics , Cell Culture Techniques , Ethyl Ethers/pharmacokinetics , Humans , Kinetics , Methyl Ethers/pharmacokinetics , Microsomes, Liver/enzymology , Oxidation-Reduction
5.
Toxicol Lett ; 110(1-2): 43-55, 1999 Oct 29.
Article in English | MEDLINE | ID: mdl-10593594

ABSTRACT

The liver microsomal fractions of seven mammalian species including rat, dog, monkey, hamster, mouse, gerbil and humans, catalyzed the hydroxylation of saturated (lauric, myristic and palmitic) and unsaturated (oleic and linoleic) fatty acids to the corresponding omega and (omega-1)-hydroxylated derivatives, while stearic acid was not metabolized. Lauric acid was the most efficiently hydroxylated, and the rank of catalytic activity was lauric > myristic > oleic > palmitic > linoleic. Among the mammalian species studied, mouse and hamster presented the highest level of fatty acid omega and (omega-1)-hydroxylases, while the lowest activity was observed in dog and monkey. In all the animal species, the (omega-1)-hydroxylation of fatty acids correlated significantly with the immunodetectable content of CYP2E1 and the 4-nitrophenol hydroxylation activity, known to be mediated by cytochrome P450 2E1. On the contrary, only the omega-hydroxylation of lauric acid slighly correlated with the level of cytochrome P450 4A, while no significant correlation was found with the omega-hydroxylation of the other fatty acids. Furthermore, chemical and immuno-inhibitions of the hydroxylations of fatty acids led to the conclusion that fatty acid (omega-1)-hydroxylase activity is catalyzed by P450 2E1 in all the mammalian species, while the fatty acid omega-hydroxylase activity may be catalyzed by cytochromes P450 from the 4A family. Therefore, lauric acid (omega-1)-hydroxylation along with 4-nitrophenol hydroxylation can be used as a specific and sensitive method to measure the level of CYP2E1 induction in humans and various animals.


Subject(s)
Cytochrome P-450 CYP2E1/metabolism , Cytochrome P-450 Enzyme System/metabolism , Fatty Acids/metabolism , Mixed Function Oxygenases/metabolism , Alkylating Agents/metabolism , Alkylation , Animals , Cricetinae , Cytochrome P-450 CYP4A , DNA/drug effects , DNA/metabolism , Dogs , Gerbillinae , Haplorhini , Humans , Hydroxylation , Immunoblotting , In Vitro Techniques , Male , Mice , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Nitroso Compounds/metabolism , Rats , Rats, Sprague-Dawley , Species Specificity
6.
Drug Metab Dispos ; 27(3): 322-6, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10064561

ABSTRACT

Hydroxylation of salicylate into 2,3 and 2,5-dihydroxybenzoic acids (2,3-DHBA and 2,5-DHBA) by human liver microsomal preparations was investigated. Kinetic studies demonstrated that salicylate was 5-hydroxylated with two apparent Km: one high-affinity Km of 606 microM and one low-affinity Km greater than 2 mM. Liver microsomes prepared from 15 human samples catalyzed the formation of 2,5-DHBA at metabolic rate of 21.7 +/- 8.5 pmol/mg/min. The formation of 2, 3-DHBA was not P-450 dependent. Formation of 2,5-DHBA was inhibited by 36 +/- 14% following preincubation of microsomes with diethyldithiocarbamate, a mechanism-based selective inhibitor of P-450 2E1. Furthermore, the efficiency of inhibition was significantly correlated with four catalytic activities specific to P-450 2E1, whereas the residual activity was correlated with three P-450 3A4 catalytic activities. Troleandomycin, a mechanism-based inhibitor selective to P-450 3A4, inhibited by 30 +/- 12% the 5-hydroxylation of salicylate, and this inhibition was significantly correlated with nifedipine oxidation, specific to P-450 3A4. The capability of seven recombinant human P-450s to hydroxylate salicylate demonstrated that P-450 2E1 and 3A4 contributed to 2, 5-DHBA formation in approximately equal proportions. The Km values of recombinant P-450 2E1 and 3A4, 280 and 513 microM, respectively, are in the same range as the high-affinity Km measured with human liver microsomes. The plasmatic metabolic ratio 2,5-DHBA/salicylate, measured 2 h after ingestion of 1 g acetylsalicylate, was increased 3-fold in 12 alcoholic patients at the beginning of their withdrawal period versus 15 control subjects. These results confirm that P-450 2E1, inducible by ethanol, is involved in the 5-hydroxylation of salicylate in humans. Furthermore, this ratio was still increased by 2-fold 1 week after ethanol withdrawal. This finding suggests that P-450 3A4, known to be also inducible by alcoholic beverages, plays an important role in this increase, because P-450 2E1 returned to normal levels in less than 3 days after ethanol withdrawal. Finally, in vivo and in vitro data demonstrated that P-450 2E1 and P-450 3A4, both inducible by alcohols, catalyzed the 5-hydroxylation of salicylate.


Subject(s)
Cytochrome P-450 CYP2E1/metabolism , Cytochrome P-450 Enzyme System/metabolism , Gentisates , Mixed Function Oxygenases/metabolism , Salicylates/metabolism , Alcoholism/enzymology , Alcoholism/metabolism , Cytochrome P-450 CYP3A , Humans , Hydroxybenzoates/metabolism , Hydroxylation , Kinetics , Microsomes, Liver/metabolism
7.
Alcohol Clin Exp Res ; 22(3): 652-7, 1998 May.
Article in English | MEDLINE | ID: mdl-9622446

ABSTRACT

The induction effects of pyrazole and dexamethasone (known to be specific to P450 2E1 and 3A enzymes, respectively), given alone or simultaneously, were studied in rat liver and kidney microsomes. Pyrazole treatment induced the catalytic activity and the amount of P450 2E1 enzyme in both organs. Immunoreactive P450 2E1 and 4-nitrophenol 2-hydroxylation increased 8- and 13-fold, respectively (versus control), in the kidney, but only 2.4- and 2.7-fold (versus control) in the liver after pyrazole treatment. As assessed by nifedipine oxidation activity, dexamethasone treatment increased the P450 3A catalytic activity approximately 4-fold (versus control) in the liver, but not in the kidney, suggesting that P450 3A was not inducible in the kidney. Pyrazole decreased P450 3A activity in the liver but did not modify it in the kidney. A combination of both chemicals induced both enzymes, but to a lesser extent than treatment with each single chemical compound. Furthermore, the 2-hydroxylation of p-nitrophenol, considered one of the most specific substrates for monitoring the level of P450 2E1, was mediated also by P450 3A, at least in dexamethasone-treated rats. Finally, this experimental work demonstrated that P450 3A induction is organ-specific, and it also demonstrated the lack of specificity of p-nitrophenol as a P450 2E1 substrate.


Subject(s)
Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 CYP2E1/metabolism , Cytochrome P-450 Enzyme System/metabolism , Dexamethasone/pharmacology , Enzyme Inhibitors/pharmacology , Kidney/enzymology , Liver/enzymology , Nitrophenols/pharmacokinetics , Oxidoreductases, N-Demethylating/metabolism , Pyrazoles/pharmacology , Animals , Cytochrome P-450 CYP3A , Enzyme Induction/drug effects , Kidney/drug effects , Liver/drug effects , Male , Rats , Rats, Wistar , Substrate Specificity
8.
Fundam Clin Pharmacol ; 12(2): 194-9, 1998.
Article in English | MEDLINE | ID: mdl-9565774

ABSTRACT

Methadone and buprenorphine, widely used in the treatment of opioid abuse, are metabolized by cytochrome P450 3A4, while fluoxetine and fluvoxamine, both selective serotonin reuptake inhibitors, are known to be P450 2D6 and 3A4 inhibitors in vitro. This study deals with the in vitro interactions between methadone or buprenorphine and fluoxetine or fluvoxamine. Fluoxetine inhibited methadone N-demethylation (Ki = 55 microM), but conversely did not inhibit buprenorphine dealkylation. Norfluoxetine inhibited the metabolism of both methadone and buprenorphine metabolisms (Ki 13 and 100 microM, respectively). Fluvoxamine inhibited methadone N-demethylation with a Ki of 7 microM and buprenorphine dealkylation, uncompetitively, with a Ki of 260 microM. Finally, these results suggest that care should be taken when selective serotonin reuptake inhibitors are administered in the treatment of drug craving. This is particularly true in the case of fluvoxamine which is more potent than fluoxetine in inhibiting methadone and buprenorphine metabolism.


Subject(s)
Buprenorphine/metabolism , Fluoxetine/pharmacology , Fluvoxamine/pharmacology , Methadone/metabolism , Microsomes, Liver/drug effects , Narcotic Antagonists/metabolism , Narcotics/metabolism , Selective Serotonin Reuptake Inhibitors/pharmacology , Buprenorphine/therapeutic use , Cytochrome P-450 Enzyme System/metabolism , Humans , In Vitro Techniques , Linear Models , Methadone/therapeutic use , Microsomes, Liver/enzymology
9.
Drug Metab Dispos ; 26(3): 257-60, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9492389

ABSTRACT

Ritonavir, indinavir, and saquinavir, all human immunodeficiency virus-1 protease inhibitors with a potent antiviral effect during triple therapy, are extensively metabolized by liver cytochrome P450 3A4. As this P450 isoform is involved in the metabolism of about 50% of drugs, coadministration of protease inhibitors with other drugs may lead to serious effects due to enzyme inhibition. Among these drugs, methadone and buprenorphine, both metabolized by P450 3A4, are potential candidates to drug interactions. In this study, metabolic interactions between these protease inhibitors and methadone or buprenorphine were studied in vitro in a panel of 13 human liver microsomes. Ritonavir was the most potent competitive inhibitor with Ki about 50 and 20 nM for methadone and buprenorphine metabolisms, respectively. Indinavir and saquinavir also inhibited methadone N-demethylation (Ki about 3 and 15 microM, respectively) and buprenorphine N-dealkylation (Ki about 0.8 and 7 microM, respectively). The rank order of inhibition potency against metabolism of methadone and buprenorphine was ritonavir > indinavir > saquinavir. There is obvious potential for clinically significant drug interactions, particularly with ritonavir. In brief, caution should be advised if human immunodeficiency virus-1 protease inhibitors are coadministered with methadone and buprenorphine.


Subject(s)
Buprenorphine/metabolism , HIV Protease Inhibitors/pharmacology , Methadone/metabolism , Alkylation/drug effects , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Humans , Indinavir/pharmacology , Kinetics , Microsomes, Liver/enzymology , Mixed Function Oxygenases/antagonists & inhibitors , Oxidoreductases, N-Demethylating/antagonists & inhibitors , Ritonavir/pharmacology , Saquinavir/pharmacology
10.
Biochem Pharmacol ; 54(8): 947-52, 1997 Oct 15.
Article in English | MEDLINE | ID: mdl-9354595

ABSTRACT

Pyrazole, acetone, and ethanol are known to induce cytochrome P450 2E1 (CYP2E1) and fatty acid (omega-1)-hydroxylation in rat liver microsomes. However, the nature of the P450 enzyme involved in this (omega-1)-hydroxylation has not been clearly established in extrahepatic tissues such as kidney. Four enzymatic activities (hydroxylations of chlorzoxazone, 4-nitrophenol, and two fatty acids) were assayed in kidney microsomal preparations of rats treated with CYP2E1 inducers. Per os treatment resulted in large increases (threefold to fivefold) in the chlorzoxazone and 4-nitrophenol hydroxylations, and up to a ninefold increase when ethanol was administered by inhalation. However, neither the omega-hydroxylation nor the (omega-1)-hydroxylation of fatty acids was modified. Immunoinhibition specific to CYP2E1 did not significantly decrease the omega and (omega-1)-lauric acid hydroxylations, while the polyclonal anti-CYP4A1 antibody inhibited in part both the omega- and (omega-1)-hydroxylations. Chemical inhibitions using either CYP2E1 competitive inhibitors (such as chlorzoxazone, DMSO, and ethanol) or P450 mechanism-based inhibitors (such as diethyldithiocarbamate and 17-octadecynoic acid) led to a partial inhibition of the hydroxylations. All these results suggest that fatty acid (omega-1)-hydroxylation, a highly specific probe for CYP2E1 in rat and human liver microsomes, is not mediated by CYP2E1 in rat kidney microsomes. In contrast to liver, where two different P450 enzymes are involved in fatty acid omega- and (omega-1)-hydroxylations, the same P450 enzyme, mainly a member of the CYP4A family, was involved in both hydroxylations in rat renal microsomes.


Subject(s)
Cytochrome P-450 CYP2E1/metabolism , Cytochrome P-450 Enzyme System/metabolism , Fatty Acids/metabolism , Kidney/enzymology , Mixed Function Oxygenases/metabolism , Animals , Chlorzoxazone/metabolism , Cytochrome P-450 CYP2E1/immunology , Cytochrome P-450 CYP2E1 Inhibitors , Cytochrome P-450 CYP4A , Enzyme Inhibitors/immunology , Enzyme Inhibitors/pharmacology , Immunologic Techniques , Male , Microsomes/enzymology , Nitrophenols/metabolism , Rats , Rats, Sprague-Dawley
11.
Mutat Res ; 377(2): 199-209, 1997 Jul 03.
Article in English | MEDLINE | ID: mdl-9247615

ABSTRACT

A panel of 14 human liver microsomal preparations metabolized at variable rates three symmetrical nitrosodialkylamines (N-nitroso-dipropyl, dibutyl and diamyl-amines, NDPA, NDBA, NDAA) into aldehydes and hydroxynitrosamines. Formation of linear aldehydes, convenient probes for alpha-hydroxylation of alkyl chain, and production of hydroxy metabolites of NDPA, NDBA and NDAA were simultaneously monitored by two specific HPLC detection methods. The longer the alkyl chain, the smaller the metabolic rate of the alpha-hydroxylation of the alkyl chain and the greater was the metabolic rate of the corresponding (omega-1)-hydroxy metabolite formation. Thus, the (omega-1)-hydroxylation of the alkyl chain was the major metabolic pathway of NDBA and NDAA in so far as it represented 3.3- and 86-fold of the alpha-hydroxylation. The balance between beta- to omega-hydroxylations and alpha-hydroxylation of carbon atoms of the alkyl chain depends upon its length and also upon the specific P450 isoform(s) involved. The hydroxylation site of the alkyl chain by P450 2E1 depends upon its length. For short alkyl chains, the main pathway was alpha-hydroxylation while for long alkyl chains, such as pentyl, (omega-1)-hydroxylation became the major pathway. The rate of alpha-hydroxylation was shown to be correlated with mutagenesis of 5 dialkylnitrosamines, as inferred from literature data, while the (omega-1)-hydroxylation was inversely correlated. Furthermore, other P450s than P450 2E1, such as P450 3A4 and 2C were shown to be involved in the metabolism of nitrosodialkylamines bearing long alkyl chains.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Microsomes, Liver/metabolism , Nitrosamines/metabolism , Adult , Carcinogens/metabolism , Cell Line , Chromatography, High Pressure Liquid , Cytochrome P-450 Enzyme System/genetics , Female , Humans , Hydroxylation , Male , Middle Aged , Mutagens/chemistry , Mutagens/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Structure-Activity Relationship
12.
Biochem Pharmacol ; 53(6): 765-71, 1997 Mar 21.
Article in English | MEDLINE | ID: mdl-9113097

ABSTRACT

Laurate and arachidonate omega and (omega-1)-hydroxylase activities, cytochrome P450 2E1 (CYP2E1), and CYP4A content were measured in 18 human kidney microsomal samples. The rates of laurate and arachidonate were found to be very different from those measured in human liver samples, with a laurate omega/omega-1 ratio of approximately 22 in human kidney vs 0.75 in human liver. Immunoblot analysis of the 18 human kidney microsomal samples identified 1 CYP4A electrophoretic band, but CYP2E1 was not detectable in human kidney, contrary to liver. Laurate and arachidonate omega-hydroxylase activities were significantly correlated with CYP4A content (r = 0.86 and 0.75, respectively). Polyclonal antirat CYP2E1 antibody did not affect omega-hydroxylase activity, whereas the polyclonal antirat CYP4A1 antibody inhibited it by 60%. These results suggest that, in contrast to other species, human kidney microsomes do not contain significant amounts of CYP2E1, but possess CYP4A and fatty acid omega-hydroxylase activity.


Subject(s)
Cytochrome P-450 CYP2E1/analysis , Cytochrome P-450 Enzyme System/analysis , Kidney/enzymology , Microsomes/enzymology , Mixed Function Oxygenases/analysis , Adult , Aged , Aged, 80 and over , Arachidonic Acid/metabolism , Cytochrome P-450 CYP4A , Female , Humans , Hydroxylation , Kinetics , Lauric Acids/metabolism , Male , Middle Aged
13.
Toxicology ; 117(1): 13-23, 1997 Feb 14.
Article in English | MEDLINE | ID: mdl-9020195

ABSTRACT

Methadone, a synthetic drug, is one of the most widely used drugs for opiate dependency treatment. This drug has been demonstrated to be extensively metabolized by cytochrome P450 3A4 in human liver microsomes. Thus, the aim of this in vitro study was to determine if methadone is an inhibitor of other P450s characterized by their specific catalytic activities. Enzymatic activities specific to P450 2E1, P450 1A, P450 2B and P450 2C were not inhibited by methadone. Conversely, nifedipine oxidation, mediated by cytochrome P450 3A4, was potently inhibited by methadone by a mixed-type inhibition mechanism with a Ki of 100 microM. Fluvoxamine, a new antidepressant, was shown to be a potent mixed-type inhibitor of methadone N-demethylation with a Ki of 7 microM. Finally, methadone appears to be a mixed-type inhibitor and not a suicide inhibitor of cytochrome P450 3A family. Accordingly, caution should be advised in the clinical use of methadone when other drugs are administered that are able to induce or inhibit P450 3A4, such as rifampicin or nifedipine, diazepam and fluvoxamine.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Cytochrome P-450 Enzyme System/pharmacology , Methadone/metabolism , Methadone/pharmacology , Mixed Function Oxygenases/metabolism , Mixed Function Oxygenases/pharmacology , Binding, Competitive/drug effects , Cytochrome P-450 CYP1A1/analysis , Cytochrome P-450 CYP2B1/analysis , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme Inhibitors , Dextromethorphan/metabolism , Diazepam/pharmacology , Fluvoxamine/pharmacology , Humans , Methadone/antagonists & inhibitors , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Microsomes, Liver/metabolism , Mixed Function Oxygenases/antagonists & inhibitors , Nifedipine/pharmacology , Rifampin/pharmacology
14.
Life Sci ; 60(22): 1953-64, 1997.
Article in English | MEDLINE | ID: mdl-9180349

ABSTRACT

Buprenorphine is a long acting analgesic of the opiate family. Recently, it has been proposed for the opioid dependency treatment at a large scale. The drug is extensively metabolized by the hepatic cytochrome P450 in man, yielding a N-dealkylated metabolite, norbuprenorphine. The specific forms of P450 involved in this oxidative N-demethylation were examined in a panel of 18 human liver microsomal preparations previously characterized with respect to their P450 contents. Buprenorphine was N-dealkylated with an apparent Km of 89 +/- 45 microM (n = 3). The metabolic rates were 3.46 +/- 0.43 nmol/(min x mg of protein). This metabolic pathway was strongly correlated with 6 catalytic activities specific to P450 3A4 and with the immunodetectable P450 3A content of liver microsomal samples (r = 0.87). Buprenorphine metabolism was 62-71% inhibited by three mechanism-based inhibitors (TAO, erythralosamine, gestodene), by nifedipine as competitive inhibitor (Ki = 129 microM) and by ketoconazole 0.6 microM (25% residual activity), all these inhibitors specific to P450 3A. Among 10 heterologously expressed P450s tested, only P450 3A4 was able to dealkylate buprenorphine with a turnover number of 9.6 min(-1). Morever, this catalytic activity was inhibited up to 80% (vs control) by anti-rat P450 3A antibody. Taken together, all these data demonstrate that P450 3A4 is the major enzyme involved in hepatic buprenorphine N-dealkylation.


Subject(s)
Buprenorphine/pharmacokinetics , Cytochrome P-450 Enzyme System/metabolism , Microsomes, Liver/metabolism , Mixed Function Oxygenases/metabolism , Narcotic Antagonists/pharmacokinetics , Alkylation , Buprenorphine/antagonists & inhibitors , Chromatography, High Pressure Liquid , Cytochrome P-450 CYP3A , Humans , Substrate Specificity
15.
Chem Res Toxicol ; 10(10): 1205-12, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9348445

ABSTRACT

4-Nitrophenol 2-hydroxylation activity was previously shown to be mainly catalyzed by P450 2E1 in animal species and humans. As this chemical compound is widely used as an in vitro probe for P450 2E1, this study was carried out to test its catalytic specificity. First, experiments were carried out on liver microsomes and hepatocyte cultures of rat treated with different inducers. Liver microsomes from pyrazole- and dexamethasone-treated rats hydroxylated p-nitrophenol with a metabolic rate increased by 2.5- and 2.7-fold vs control. Dexamethasone treatment increased the hepatic content of P450 3A but not that of P450 2E1. Two specific inhibitors of P450 3A catalytic activities, namely, ketoconazole and troleandomycin (TAO), inhibited up to 50% of 4-nitrophenol hydroxylation in dexamethasone-treated rats but not in controls. Hepatocyte cultures from dexamethasone-treated rats transformed p-nitrophenol into 4-nitrocatechol 7.8 times more than controls. This catalytic activity was inhibited by TAO. Similarly, hepatocyte cultures from pyrazole-treated rats hydroxylated p-nitrophenol with a metabolic ratio increased by about 8-fold vs control. This reaction was inhibited by diethyl dithiocarbamate and dimethyl sulfoxide, both inhibitors of P450 2E1. Second, the capability of human P450s other than P450 2E1 to catalyze the formation of 4-nitrocatechol was examined in a panel of 13 human liver microsomes. Diethyl dithiocarbamate and ketoconazole reduced 4-nitrophenol hydroxylase activity by 77% (+/- 11) and 13% (+/- 16), respectively. Furthermore, the residual activity following diethyl dithiocarbamate inhibition was significantly correlated with seven P450 3A4 catalytic activities. Finally, the use of human cell lines genetically engineered for expression of human P450s demonstrated that P450 2E1 and 3A4 hydroxylated 4-nitrophenol with turnovers of 19.5 and 1.65 min-1, respectively. In conclusion, P450 3A may make a significant contribution to 4-nitrophenol hydroxylase activity in man and rat.


Subject(s)
Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 CYP2E1/physiology , Cytochrome P-450 Enzyme System/physiology , Nitrophenols/metabolism , Oxidoreductases, N-Demethylating/physiology , Animals , Cells, Cultured , Cytochrome P-450 CYP3A , Humans , Hydroxylation , Kinetics , Liver/cytology , Liver/metabolism , Male , Microsomes, Liver/metabolism , Rats , Rats, Wistar , Substrate Specificity
16.
Biochem Pharmacol ; 52(12): 1915-9, 1996 Dec 24.
Article in English | MEDLINE | ID: mdl-8951351

ABSTRACT

Caffeine metabolism by hepatic microsomal P450 enzymes is well documented in experimental animals and humans. However, its induction effect on P450 enzymes has not been thoroughly studied. In a preliminary experiment, the time-dependent incubation of 1 mM caffeine with rat hepatocyte culture resulted in an increase of its own metabolic rate. The dose-dependent expression of rat hepatic and renal cytochromes (CYP) 1A1/1A2 was then investigated after per os administration of caffeine. P450 expression was monitored by using specific enzymatic activities and Northern blot analysis. Caffeine caused a dose-dependent elevation of hepatic CYP1A1/1A2 activities in microsomal preparations, which ranged from 1.7- to 6-fold for ethoxyresorufin O-deethylase and 3- to 8.9-fold for methoxy-resorufin O-demethylase according to the dose regimen of 50 and 150 mg caffeine/kg/day for 3 days, respectively. Northern blot analysis demonstrated that caffeine treatment increased liver CYP1A1 and CYP1A2 mRNA levels over the dose regimen of 50-150 mg caffeine/kg/day for 3 days, respectively. The result of this study demonstrates that caffeine increases its own metabolism in a dose-dependent manner and induces CYP1A1/1A2 expression through either transcriptional activation or mRNA stabilization.


Subject(s)
Cytochrome P-450 CYP1A1/biosynthesis , Cytochrome P-450 CYP1A2/biosynthesis , Animals , Cells, Cultured , Enzyme Induction/drug effects , Gene Expression Regulation, Enzymologic/drug effects , Kidney/enzymology , Male , Microsomes, Liver/enzymology , RNA, Messenger/genetics , Rats , Rats, Wistar
17.
Cancer Lett ; 108(2): 171-8, 1996 Nov 29.
Article in English | MEDLINE | ID: mdl-8973591

ABSTRACT

Liver microsomal preparations from control and treated rats (cytochromes P450 1A, 2B, 3A and 2E1-induced) metabolized at variable metabolic rates three nitrosodialkylamines (N-nitroso-dipropyl, dibutyl and diamyl-amines) into aldehydes and hydroxy-nitrosamines. The longer the alkyl chain, the smaller was the metabolic rate of the alpha-hydroxylation of alkyl chain yielding aldehyde and the greater was the metabolic rate of the corresponding (omega-1)-hydroxyl metabolite formation. Thus, the (omega-1) hydroxylation of the alkyl chain was the major metabolic pathway of N-nitrosodiamylamine (NDAA) so far as it represented 22-fold the alpha-hydroxylation. The balance between beta to omega hydroxylation and alpha-hydroxylation depends upon the alkyl chain length and also on specific P450 isoform induction.


Subject(s)
Carcinogens/metabolism , Microsomes, Liver/metabolism , Nitrosamines/metabolism , Animals , Carbon/metabolism , Carcinogens/chemistry , Hydroxylation , Nitrosamines/chemistry , Rats
18.
Carcinogenesis ; 17(9): 2029-34, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8824531

ABSTRACT

The metabolic dealkylation of nine nitrosodialkylamines, including five symmetrical (nitrosodimethylamine, nitrosodiethylamine, nitrosodipropylamine, nitrosodibutylamine and nitrosodiamylamine) and four asymmetrical nitrosodialkylamines (nitrosomethylethylamine, nitrosomethylpropylamine, nitrosomethylbutylamine and nitrosomethylamylamine), was investigated in 14 samples of human liver microsomes. All these nitrosodialkylamines were dealkytated to aldehydes that were separated by reversed phase HPLC and UV detected as dinitrophenylhydrazones. As the length of the alkyl chain increased from methyl to pentyl, dealkylation of symmetrical nitrosodialkylamines became less efficiently catalyzed by cytochrome P450. Conversely, oxidation of the methyl moiety of asymmetrical nitrosomethylalkylamines increased with the size of the alkyl moiety, while dealkylation of the longer alkyl group decreased. N-Dealkylase activities were significantly correlated with P450 activities measured in human liver microsomes. These catalytic activities involve CYP2A6 (coumarin 7-hydroxylation), CYP2C (mephenytoin 4-hydroxylation and tolbutamide hydroxylation), CYP2D6 (dextromethorphan O-demethylation), CYP2E1 (chlorzoxazone and p-nitrophenol hydroxylation) and CYP3A4 (nifedipine oxidation). By using 10 heterologously expressed P450s, it was shown that nitrosodimethylamine was mainly demethylated by CYP2E1. However, such enzyme specificity was lost with increasing size of the alkyl group. Therefore, the chain length of the alkyl group of nitrosodialkylamines determined the P450 involved in its oxidation. All these results emphasize that the catalytic site of P450 2EI has a geometric configuration such that only small molecules like nitrosodimethylamine fit favorably within the putative active site of the enzyme. Furthermore, there is good evidence that P450s other than P450 2E1, such as P450 2A6, 2C8/2C9/2C19 and 3A4, are involved in the metabolism of nitrosodialkylamines bearing bulky alkyl chains.


Subject(s)
Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 Enzyme System/metabolism , Microsomes, Liver/enzymology , Nitrosamines/metabolism , Adult , Biotransformation , Cytochrome P-450 CYP2A6 , Cytochrome P-450 CYP2C19 , Cytochrome P-450 CYP2D6/metabolism , Cytochrome P-450 CYP2E1/metabolism , Cytochrome P-450 CYP3A , Female , Humans , Kinetics , Male , Mixed Function Oxygenases/metabolism , Recombinant Proteins/metabolism , Substrate Specificity
19.
Alcohol ; 13(3): 301-8, 1996.
Article in English | MEDLINE | ID: mdl-8734847

ABSTRACT

Ethanol consumption combined with smoking increase the risk of cancer in many tissues. Such a mechanism implies the involvement of cytochrome P450 alcohol (CYP2E1), which is regulated by numerous xenobiotics. The combination of P450 2E1 inducers (acetone or pyridine) and 3-methylcholanthrene during rat treatment was shown to decrease the liver P450 2E1 content while it enhanced its expression in kidney. It is suggested that this differential tissue response helps explain the organotropy of nitrosamine carcinogenicity.


Subject(s)
Carcinogens/pharmacology , Cytochrome P-450 Enzyme System/genetics , Gene Expression/drug effects , Kidney/enzymology , Liver/enzymology , Lung/enzymology , Oxidoreductases, N-Demethylating/genetics , Acetone/pharmacology , Animals , Base Sequence , Blotting, Northern , Cytochrome P-450 CYP2E1 , Male , Methylcholanthrene/pharmacology , Molecular Sequence Data , Pyridines/pharmacology , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley
20.
Chem Res Toxicol ; 9(2): 365-73, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8839037

ABSTRACT

Methadone has become one of the most widely used drugs for opiate dependency treatment. This drug is extensively metabolized by the cytochrome P450 hepatic enzyme family in man, yielding an N-demethylated metabolite that cyclizes spontaneously into 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine. The specific forms of cytochrome P450 involved in this oxidative N-demethylation were examined in a panel of 20 human liver microsomal preparations previously characterized with respect to their P450 enzyme contents. Methadone was demethylated with an apparent Km of 545 +/- 258 microM (n = 3). The metabolic rates were 745 +/- 574 pmol/(min.mg of protein). This metabolic pathway was strongly correlated with estradiol 2-hydroxylation, testosterone 6 beta-hydroxylation, nifedipine oxidation, erythromycin N-demethylation, and toremifene N-demethylation, all of these monooxygenase activities being supported by P450 3A4. Furthermore, the total P450 3A content of liver microsomal samples, determined by immuno-quantification using a monoclonal anti-human P450 3A4 antibody, was correlated with methadone demethylation (r = 0.72; p < 0.003). Methadone metabolism was 60-72% inhibited either by three mechanism-based inhibitors of P450 3A4 (gestodene, TAO, and erythralosamine) or by four reversible inhibitors of P450 3A (ketoconazole, dihydroergotamine, quercetin, and diazepam with an apparent Ki of 50 microM) and by two nonspecific inhibitors (metyrapone and SKF-525A). Conversely, quinidine (inhibitor of P450 2D6), 7,8-benzoflavone (inhibitor of P450 1A), or sulfaphenazole (inhibitor of P450 2C) did not significantly inhibit, and may even have activated, methadone metabolism. Four heterologously expressed P450 proteins were able to catalyze the N-demethylation of methadone, namely, P450 2C8, P450 2C18, P450 2D6, and P450 3A4. However, referring to their relative liver content, it can be asserted that P450 3A4 is the major enzyme involved in the N-demethylation of methadone on average. Accordingly, caution should be advised in the clinical use of methadone when other drugs are also administered that induce or inhibit P450 3A4, such as rifampicin or diazepam, respectively.


Subject(s)
Cytochrome P-450 Enzyme System/physiology , Methadone/metabolism , Microsomes, Liver/enzymology , Mixed Function Oxygenases/physiology , Oxidoreductases, N-Demethylating/metabolism , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme System/metabolism , Humans , Kinetics , Microsomes, Liver/drug effects , Mixed Function Oxygenases/metabolism , Oxidation-Reduction
SELECTION OF CITATIONS
SEARCH DETAIL
...